CA2577999A1 - Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues - Google Patents

Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues Download PDF

Info

Publication number: CA2577999A1
Authority: CA; Canada
Prior art keywords: hgh; peg; growth hormone; conjugate; growth
Prior art date: 2004-08-31
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002577999A

Other languages

English (en)

Inventor

Rory F. Finn

Ned R. Siegel

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Pharmacia and Upjohn Co LLC

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-08-31

Filing date

2005-08-25

Publication date

2006-03-09

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2577999(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-08-25 Application filed by Individual filed Critical Individual

2006-03-09 Publication of CA2577999A1 publication Critical patent/CA2577999A1/fr

Status Abandoned legal-status Critical Current

Links

108010000521 Human Growth Hormone Proteins 0.000 title claims abstract description 225
102000002265 Human Growth Hormone Human genes 0.000 title claims abstract description 225
239000000854 Human Growth Hormone Substances 0.000 title claims abstract description 212
238000000034 method Methods 0.000 title claims abstract description 33
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 title abstract description 161
230000008569 process Effects 0.000 title abstract description 11
229920001223 polyethylene glycol Polymers 0.000 title description 110
239000002202 Polyethylene glycol Substances 0.000 title description 10
238000002360 preparation method Methods 0.000 title description 9
230000012010 growth Effects 0.000 claims abstract description 28
238000011282 treatment Methods 0.000 claims abstract description 22
208000037824 growth disorder Diseases 0.000 claims abstract description 6
206010012559 Developmental delay Diseases 0.000 claims abstract description 5
-1 polyethylene Polymers 0.000 claims description 62
206010056438 Growth hormone deficiency Diseases 0.000 claims description 9
125000003277 amino group Chemical group 0.000 claims description 9
208000020832 chronic kidney disease Diseases 0.000 claims description 9
241000282414 Homo sapiens Species 0.000 claims description 7
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 claims description 6
COLNVLDHVKWLRT-QMMMGPOBSA-N phenylalanine group Chemical group N[C@@H](CC1=CC=CC=C1)C(=O)O COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 claims description 6
206010053759 Growth retardation Diseases 0.000 claims description 5
208000026928 Turner syndrome Diseases 0.000 claims description 4
239000003862 glucocorticoid Substances 0.000 claims description 4
208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
206010029748 Noonan syndrome Diseases 0.000 claims description 3
208000030886 Traumatic Brain injury Diseases 0.000 claims description 3
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
125000003275 alpha amino acid group Chemical group 0.000 claims description 3
201000000523 end stage renal failure Diseases 0.000 claims description 3
208000018773 low birth weight Diseases 0.000 claims description 3
231100000533 low birth weight Toxicity 0.000 claims description 3
230000009529 traumatic brain injury Effects 0.000 claims description 3
208000011231 Crohn disease Diseases 0.000 claims description 2
201000010374 Down Syndrome Diseases 0.000 claims description 2
208000010228 Erectile Dysfunction Diseases 0.000 claims description 2
208000001640 Fibromyalgia Diseases 0.000 claims description 2
206010049287 Lipodystrophy acquired Diseases 0.000 claims description 2
208000026139 Memory disease Diseases 0.000 claims description 2
208000021642 Muscular disease Diseases 0.000 claims description 2
201000009623 Myopathy Diseases 0.000 claims description 2
208000001132 Osteoporosis Diseases 0.000 claims description 2
239000004698 Polyethylene Substances 0.000 claims description 2
208000020221 Short stature Diseases 0.000 claims description 2
206010072610 Skeletal dysplasia Diseases 0.000 claims description 2
208000032851 Subarachnoid Hemorrhage Diseases 0.000 claims description 2
206010044688 Trisomy 21 Diseases 0.000 claims description 2
210000001185 bone marrow Anatomy 0.000 claims description 2
201000001881 impotence Diseases 0.000 claims description 2
208000006132 lipodystrophy Diseases 0.000 claims description 2
229920000573 polyethylene Polymers 0.000 claims description 2
230000002028 premature Effects 0.000 claims description 2
210000000130 stem cell Anatomy 0.000 claims description 2
230000006320 pegylation Effects 0.000 abstract description 14
239000008194 pharmaceutical composition Substances 0.000 abstract description 4
150000001299 aldehydes Chemical class 0.000 description 44
229920000642 polymer Polymers 0.000 description 33
108090000623 proteins and genes Proteins 0.000 description 30
235000018102 proteins Nutrition 0.000 description 27
102000004169 proteins and genes Human genes 0.000 description 27
239000000122 growth hormone Substances 0.000 description 26
102000018997 Growth Hormone Human genes 0.000 description 24
108010051696 Growth Hormone Proteins 0.000 description 24
241000894007 species Species 0.000 description 24
241000700159 Rattus Species 0.000 description 20
239000000126 substance Substances 0.000 description 20
238000006243 chemical reaction Methods 0.000 description 19
239000003814 drug Substances 0.000 description 18
241001465754 Metazoa Species 0.000 description 16
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 15
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
235000019786 weight gain Nutrition 0.000 description 15
230000004584 weight gain Effects 0.000 description 14
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
230000021615 conjugation Effects 0.000 description 12
230000003247 decreasing effect Effects 0.000 description 11
239000011541 reaction mixture Substances 0.000 description 11
102000005962 receptors Human genes 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
239000000872 buffer Substances 0.000 description 10
239000000047 product Substances 0.000 description 10
239000000243 solution Substances 0.000 description 10
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical group OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 9
239000000556 agonist Substances 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
239000008280 blood Substances 0.000 description 9
238000000746 purification Methods 0.000 description 9
239000004094 surface-active agent Substances 0.000 description 9
230000004071 biological effect Effects 0.000 description 8
208000035475 disorder Diseases 0.000 description 8
235000018977 lysine Nutrition 0.000 description 8
239000000203 mixture Substances 0.000 description 8
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 7
201000010099 disease Diseases 0.000 description 7
238000000338 in vitro Methods 0.000 description 7
238000005932 reductive alkylation reaction Methods 0.000 description 7
210000002966 serum Anatomy 0.000 description 7
229940124597 therapeutic agent Drugs 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 6
239000004472 Lysine Substances 0.000 description 6
NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 6
238000004458 analytical method Methods 0.000 description 6
239000003957 anion exchange resin Substances 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
230000000694 effects Effects 0.000 description 6
238000010828 elution Methods 0.000 description 6
238000004255 ion exchange chromatography Methods 0.000 description 6
229920001427 mPEG Polymers 0.000 description 6
230000004048 modification Effects 0.000 description 6
238000012986 modification Methods 0.000 description 6
230000002265 prevention Effects 0.000 description 6
230000004044 response Effects 0.000 description 6
210000002303 tibia Anatomy 0.000 description 6
239000003981 vehicle Substances 0.000 description 6
201000010769 Prader-Willi syndrome Diseases 0.000 description 5
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 5
230000032683 aging Effects 0.000 description 5
239000003795 chemical substances by application Substances 0.000 description 5
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 5
239000013628 high molecular weight specie Substances 0.000 description 5
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 5
239000000463 material Substances 0.000 description 5
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 description 5
229920000233 poly(alkylene oxides) Polymers 0.000 description 5
238000003998 size exclusion chromatography high performance liquid chromatography Methods 0.000 description 5
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
102000004190 Enzymes Human genes 0.000 description 4
108090000790 Enzymes Proteins 0.000 description 4
241000124008 Mammalia Species 0.000 description 4
239000012614 Q-Sepharose Substances 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
102100022831 Somatoliberin Human genes 0.000 description 4
101710142969 Somatoliberin Proteins 0.000 description 4
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
238000003556 assay Methods 0.000 description 4
230000009286 beneficial effect Effects 0.000 description 4
239000003729 cation exchange resin Substances 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
230000000670 limiting effect Effects 0.000 description 4
PKWDZWYVIHVNKS-UHFFFAOYSA-N netoglitazone Chemical compound FC1=CC=CC=C1COC1=CC=C(C=C(CC2C(NC(=O)S2)=O)C=C2)C2=C1 PKWDZWYVIHVNKS-UHFFFAOYSA-N 0.000 description 4
102000004196 processed proteins & peptides Human genes 0.000 description 4
108090000765 processed proteins & peptides Proteins 0.000 description 4
150000003839 salts Chemical class 0.000 description 4
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
238000002965 ELISA Methods 0.000 description 3
239000007995 HEPES buffer Substances 0.000 description 3
108090001117 Insulin-Like Growth Factor II Proteins 0.000 description 3
102000048143 Insulin-Like Growth Factor II Human genes 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000004913 activation Effects 0.000 description 3
210000000577 adipose tissue Anatomy 0.000 description 3
125000002947 alkylene group Chemical group 0.000 description 3
238000005571 anion exchange chromatography Methods 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
230000008901 benefit Effects 0.000 description 3
229960002938 bexarotene Drugs 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
230000015556 catabolic process Effects 0.000 description 3
229940023913 cation exchange resins Drugs 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
230000001268 conjugating effect Effects 0.000 description 3
229920001577 copolymer Polymers 0.000 description 3
238000010168 coupling process Methods 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000006731 degradation reaction Methods 0.000 description 3
239000012634 fragment Substances 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
CDAISMWEOUEBRE-UHFFFAOYSA-N inositol Chemical compound OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 3
230000003993 interaction Effects 0.000 description 3
125000005647 linker group Chemical group 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
230000001766 physiological effect Effects 0.000 description 3
229920001515 polyalkylene glycol Polymers 0.000 description 3
229920001184 polypeptide Polymers 0.000 description 3
150000003141 primary amines Chemical class 0.000 description 3
230000009467 reduction Effects 0.000 description 3
238000006722 reduction reaction Methods 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
238000000926 separation method Methods 0.000 description 3
238000001542 size-exclusion chromatography Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
239000003643 water by type Substances 0.000 description 3
229920003169 water-soluble polymer Polymers 0.000 description 3
230000003442 weekly effect Effects 0.000 description 3
RVWNMGKSNGWLOL-GIIHNPQRSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(2-methyl-1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 RVWNMGKSNGWLOL-GIIHNPQRSA-N 0.000 description 2
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
QBQLYIISSRXYKL-UHFFFAOYSA-N 4-[[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]methyl]-1,2-oxazolidine-3,5-dione Chemical compound CC=1OC(C=2C=CC=CC=2)=NC=1CCOC(C=C1)=CC=C1CC1C(=O)NOC1=O QBQLYIISSRXYKL-UHFFFAOYSA-N 0.000 description 2
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
ZTQSAGDEMFDKMZ-UHFFFAOYSA-N Butyraldehyde Chemical compound CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
229920002307 Dextran Polymers 0.000 description 2
206010013883 Dwarfism Diseases 0.000 description 2
102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 2
101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
102000004877 Insulin Human genes 0.000 description 2
108090001061 Insulin Proteins 0.000 description 2
108090000965 Insulin-like growth factor binding protein 3 Proteins 0.000 description 2
102100022708 Insulin-like growth factor-binding protein 3 Human genes 0.000 description 2
239000007836 KH2PO4 Substances 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical compound Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
102000013275 Somatomedins Human genes 0.000 description 2
102000004142 Trypsin Human genes 0.000 description 2
108090000631 Trypsin Proteins 0.000 description 2
238000002835 absorbance Methods 0.000 description 2
235000001014 amino acid Nutrition 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000003698 anagen phase Effects 0.000 description 2
238000005349 anion exchange Methods 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
238000013459 approach Methods 0.000 description 2
229920001400 block copolymer Polymers 0.000 description 2
230000037396 body weight Effects 0.000 description 2
NNTOJPXOCKCMKR-UHFFFAOYSA-N boron;pyridine Chemical compound [B].C1=CC=NC=C1 NNTOJPXOCKCMKR-UHFFFAOYSA-N 0.000 description 2
108010006025 bovine growth hormone Proteins 0.000 description 2
229910052799 carbon Inorganic materials 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000003638 chemical reducing agent Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
230000002950 deficient Effects 0.000 description 2
108010005905 delta-hGHR Proteins 0.000 description 2
238000011161 development Methods 0.000 description 2
230000018109 developmental process Effects 0.000 description 2
230000001904 diabetogenic effect Effects 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
229910000396 dipotassium phosphate Inorganic materials 0.000 description 2
235000019797 dipotassium phosphate Nutrition 0.000 description 2
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
229910000397 disodium phosphate Inorganic materials 0.000 description 2
235000019800 disodium phosphate Nutrition 0.000 description 2
239000012149 elution buffer Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
206010016165 failure to thrive Diseases 0.000 description 2
125000003827 glycol group Chemical group 0.000 description 2
150000002334 glycols Chemical class 0.000 description 2
238000004128 high performance liquid chromatography Methods 0.000 description 2
229920001519 homopolymer Polymers 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
238000004191 hydrophobic interaction chromatography Methods 0.000 description 2
230000005847 immunogenicity Effects 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
229940125396 insulin Drugs 0.000 description 2
230000002608 insulinlike Effects 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
230000006651 lactation Effects 0.000 description 2
230000037356 lipid metabolism Effects 0.000 description 2
210000004185 liver Anatomy 0.000 description 2
229920002521 macromolecule Polymers 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
238000005259 measurement Methods 0.000 description 2
239000012528 membrane Substances 0.000 description 2
230000002503 metabolic effect Effects 0.000 description 2
125000000896 monocarboxylic acid group Chemical group 0.000 description 2
229910000402 monopotassium phosphate Inorganic materials 0.000 description 2
235000019796 monopotassium phosphate Nutrition 0.000 description 2
235000019799 monosodium phosphate Nutrition 0.000 description 2
229910052757 nitrogen Inorganic materials 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
238000001543 one-way ANOVA Methods 0.000 description 2
238000012510 peptide mapping method Methods 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
229920002451 polyvinyl alcohol Polymers 0.000 description 2
GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
230000017854 proteolysis Effects 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
229960004586 rosiglitazone Drugs 0.000 description 2
SUFUKZSWUHZXAV-BTJKTKAUSA-N rosiglitazone maleate Chemical compound [H+].[H+].[O-]C(=O)\C=C/C([O-])=O.C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O SUFUKZSWUHZXAV-BTJKTKAUSA-N 0.000 description 2
150000003335 secondary amines Chemical class 0.000 description 2
230000000580 secretagogue effect Effects 0.000 description 2
230000001235 sensitizing effect Effects 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
235000017557 sodium bicarbonate Nutrition 0.000 description 2
AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
229910000162 sodium phosphate Inorganic materials 0.000 description 2
238000013223 sprague-dawley female rat Methods 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
238000010254 subcutaneous injection Methods 0.000 description 2
239000007929 subcutaneous injection Substances 0.000 description 2
238000006467 substitution reaction Methods 0.000 description 2
238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
229940099419 targretin Drugs 0.000 description 2
125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 2
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 description 2
229960001641 troglitazone Drugs 0.000 description 2
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 description 2
239000012588 trypsin Substances 0.000 description 2
238000000108 ultra-filtration Methods 0.000 description 2
AASBXERNXVFUEJ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) propanoate Chemical compound CCC(=O)ON1C(=O)CCC1=O AASBXERNXVFUEJ-UHFFFAOYSA-N 0.000 description 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
RDGUFKZGMLPVHL-QFIPXVFZSA-N (2s)-3-[4-[2-(5-methyl-2-phenyl-1,3-oxazol-4-yl)ethoxy]phenyl]-2-(propylamino)propanoic acid Chemical compound C1=CC(C[C@H](NCCC)C(O)=O)=CC=C1OCCC1=C(C)OC(C=2C=CC=CC=2)=N1 RDGUFKZGMLPVHL-QFIPXVFZSA-N 0.000 description 1
NWQWNCILOXTTHF-HLCSKTDOSA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-aminopropanoyl]amino]-3-(1h-imidazol-5-yl)propanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@@H](N)C)C(=O)N[C@H](CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CNC=N1 NWQWNCILOXTTHF-HLCSKTDOSA-N 0.000 description 1
WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
HRNLPPBUBKMZMT-SSSXJSFTSA-N (2s)-6-amino-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2r)-2-aminopropanoyl]amino]-3-naphthalen-2-ylpropanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](C)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(=O)[C@H](N)C)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 HRNLPPBUBKMZMT-SSSXJSFTSA-N 0.000 description 1
WURGZWOTGMLDJP-ZCYANPAGSA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl-[(2r)-1-(methylamino)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound C([C@H](C(=O)NC)N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)C1=CC=CC=C1 WURGZWOTGMLDJP-ZCYANPAGSA-N 0.000 description 1
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
ASUGWWOMVNVWAW-UHFFFAOYSA-N 1-(2-methoxyethyl)pyrrole-2,5-dione Chemical compound COCCN1C(=O)C=CC1=O ASUGWWOMVNVWAW-UHFFFAOYSA-N 0.000 description 1
KVGOXGQSTGQXDD-UHFFFAOYSA-N 1-decane-sulfonic-acid Chemical compound CCCCCCCCCCS(O)(=O)=O KVGOXGQSTGQXDD-UHFFFAOYSA-N 0.000 description 1
LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
CDAISMWEOUEBRE-LKPKBOIGSA-N 1D-chiro-inositol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-LKPKBOIGSA-N 0.000 description 1
XLKDJOPOOHHZAN-UHFFFAOYSA-N 1h-pyrrolo[2,3-c]pyridine Chemical class C1=NC=C2NC=CC2=C1 XLKDJOPOOHHZAN-UHFFFAOYSA-N 0.000 description 1
KCEFVYIWOQSJCH-LMOVPXPDSA-N 2-[4-[2-[[(2r)-2-hydroxy-2-phenylethyl]amino]ethoxy]phenyl]acetic acid;hydrochloride Chemical compound Cl.C([C@H](O)C=1C=CC=CC=1)NCCOC1=CC=C(CC(O)=O)C=C1 KCEFVYIWOQSJCH-LMOVPXPDSA-N 0.000 description 1
CCTREOMTIFSZAU-OGFXRTJISA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;5-[(3r)-dithiolan-3-yl]pentanoic acid Chemical compound OCC(N)(CO)CO.OC(=O)CCCC[C@@H]1CCSS1 CCTREOMTIFSZAU-OGFXRTJISA-N 0.000 description 1
OPUPBQQWLWFCPU-UHFFFAOYSA-N 2-benzylbenzamide Chemical compound NC(=O)C1=CC=CC=C1CC1=CC=CC=C1 OPUPBQQWLWFCPU-UHFFFAOYSA-N 0.000 description 1
BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
ILPUOPPYSQEBNJ-UHFFFAOYSA-N 2-methyl-2-phenoxypropanoic acid Chemical class OC(=O)C(C)(C)OC1=CC=CC=C1 ILPUOPPYSQEBNJ-UHFFFAOYSA-N 0.000 description 1
CLPFFLWZZBQMAO-UHFFFAOYSA-N 4-(5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl)benzonitrile Chemical compound C1=CC(C#N)=CC=C1C1N2C=NC=C2CCC1 CLPFFLWZZBQMAO-UHFFFAOYSA-N 0.000 description 1
PCAZCAZVHLGDBA-UHFFFAOYSA-N 5-[[4-(2-indol-1-ylethoxy)phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC(C=C1)=CC=C1OCCN1C2=CC=CC=C2C=C1 PCAZCAZVHLGDBA-UHFFFAOYSA-N 0.000 description 1
IETKPTYAGKZLKY-UHFFFAOYSA-N 5-[[4-[(3-methyl-4-oxoquinazolin-2-yl)methoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound N=1C2=CC=CC=C2C(=O)N(C)C=1COC(C=C1)=CC=C1CC1SC(=O)NC1=O IETKPTYAGKZLKY-UHFFFAOYSA-N 0.000 description 1
ZLUWVRIZBDJIOF-UHFFFAOYSA-N 5-[[4-[[4-[(2,4-dioxo-1,3-thiazolidin-5-yl)methyl]phenyl]methyl]phenyl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC(C=C1)=CC=C1CC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 ZLUWVRIZBDJIOF-UHFFFAOYSA-N 0.000 description 1
DHSSDEDRBUKTQY-UHFFFAOYSA-N 6-prop-2-enyl-4,5,7,8-tetrahydrothiazolo[4,5-d]azepin-2-amine Chemical compound C1CN(CC=C)CCC2=C1N=C(N)S2 DHSSDEDRBUKTQY-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
DJQOOSBJCLSSEY-UHFFFAOYSA-N Acipimox Chemical compound CC1=CN=C(C(O)=O)C=[N+]1[O-] DJQOOSBJCLSSEY-UHFFFAOYSA-N 0.000 description 1
102100033367 Appetite-regulating hormone Human genes 0.000 description 1
BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
241000271566 Aves Species 0.000 description 1
239000007992 BES buffer Substances 0.000 description 1
229940123208 Biguanide Drugs 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
KPSRODZRAIWAKH-JTQLQIEISA-N Ciprofibrate Natural products C1=CC(OC(C)(C)C(O)=O)=CC=C1[C@H]1C(Cl)(Cl)C1 KPSRODZRAIWAKH-JTQLQIEISA-N 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
201000003883 Cystic fibrosis Diseases 0.000 description 1
108020004414 DNA Proteins 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 description 1
102000003779 Dipeptidyl-peptidases and tripeptidyl-peptidases Human genes 0.000 description 1
108090000194 Dipeptidyl-peptidases and tripeptidyl-peptidases Proteins 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000588724 Escherichia coli Species 0.000 description 1
101710115821 Flavin reductase (NADPH) Proteins 0.000 description 1
HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 description 1
101000930822 Giardia intestinalis Dipeptidyl-peptidase 4 Proteins 0.000 description 1
102100033299 Glia-derived nexin Human genes 0.000 description 1
101710183811 Glia-derived nexin Proteins 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 1
102100020948 Growth hormone receptor Human genes 0.000 description 1
101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
101001075374 Homo sapiens Gamma-glutamyl hydrolase Proteins 0.000 description 1
101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 1
101001076292 Homo sapiens Insulin-like growth factor II Proteins 0.000 description 1
101001123448 Homo sapiens Prolactin receptor Proteins 0.000 description 1
101000664737 Homo sapiens Somatotropin Proteins 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
101150002416 Igf2 gene Proteins 0.000 description 1
102100023915 Insulin Human genes 0.000 description 1
102100037852 Insulin-like growth factor I Human genes 0.000 description 1
102100025947 Insulin-like growth factor II Human genes 0.000 description 1
VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
102000004472 Myostatin Human genes 0.000 description 1
108010056852 Myostatin Proteins 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
229910020889 NaBH3 Inorganic materials 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
102000000536 PPAR gamma Human genes 0.000 description 1
108010016731 PPAR gamma Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
102000003728 Peroxisome Proliferator-Activated Receptors Human genes 0.000 description 1
108090000029 Peroxisome Proliferator-Activated Receptors Proteins 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
102000004576 Placental Lactogen Human genes 0.000 description 1
108010003044 Placental Lactogen Proteins 0.000 description 1
239000000381 Placental Lactogen Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010002519 Prolactin Receptors Proteins 0.000 description 1
102100029000 Prolactin receptor Human genes 0.000 description 1
102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
RVOLLAQWKVFTGE-UHFFFAOYSA-N Pyridostigmine Chemical compound CN(C)C(=O)OC1=CC=C[N+](C)=C1 RVOLLAQWKVFTGE-UHFFFAOYSA-N 0.000 description 1
101100288143 Rattus norvegicus Klkb1 gene Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
102000005157 Somatostatin Human genes 0.000 description 1
108010056088 Somatostatin Proteins 0.000 description 1
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 1
239000012505 Superdex™ Substances 0.000 description 1
WBWWGRHZICKQGZ-UHFFFAOYSA-N Taurocholic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(=O)NCCS(O)(=O)=O)C)C1(C)C(O)C2 WBWWGRHZICKQGZ-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
239000002253 acid Substances 0.000 description 1
229960003526 acipimox Drugs 0.000 description 1
229940062328 actos Drugs 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000000048 adrenergic agonist Substances 0.000 description 1
108010083553 alanyl-histidyl-(2-naphthyl)alanyl-tryptophyl-phenylalanyl-lysinamide Proteins 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
235000012501 ammonium carbonate Nutrition 0.000 description 1
235000019270 ammonium chloride Nutrition 0.000 description 1
229940124325 anabolic agent Drugs 0.000 description 1
239000003263 anabolic agent Substances 0.000 description 1
229960002932 anastrozole Drugs 0.000 description 1
YBBLVLTVTVSKRW-UHFFFAOYSA-N anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003886 aromatase inhibitor Substances 0.000 description 1
229940046844 aromatase inhibitors Drugs 0.000 description 1
229950004810 atamestane Drugs 0.000 description 1
PEPMWUSGRKINHX-TXTPUJOMSA-N atamestane Chemical compound C1C[C@@H]2[C@@]3(C)C(C)=CC(=O)C=C3CC[C@H]2[C@@H]2CCC(=O)[C@]21C PEPMWUSGRKINHX-TXTPUJOMSA-N 0.000 description 1
229940062310 avandia Drugs 0.000 description 1
235000021053 average weight gain Nutrition 0.000 description 1
ZSIQJIWKELUFRJ-UHFFFAOYSA-N azepane Chemical class C1CCCNCC1 ZSIQJIWKELUFRJ-UHFFFAOYSA-N 0.000 description 1
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 1
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
229960000516 bezafibrate Drugs 0.000 description 1
IIBYAHWJQTYFKB-UHFFFAOYSA-N bezafibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1CCNC(=O)C1=CC=C(Cl)C=C1 IIBYAHWJQTYFKB-UHFFFAOYSA-N 0.000 description 1
150000004283 biguanides Chemical class 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000000975 bioactive effect Effects 0.000 description 1
230000008033 biological extinction Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
229940088623 biologically active substance Drugs 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
230000036765 blood level Effects 0.000 description 1
230000008468 bone growth Effects 0.000 description 1
239000000337 buffer salt Substances 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
KVLLHLWBPNCVNR-SKCUWOTOSA-N capromorelin Chemical compound C([C@@]12CN(CCC1=NN(C2=O)C)C(=O)[C@@H](COCC=1C=CC=CC=1)NC(=O)C(C)(C)N)C1=CC=CC=C1 KVLLHLWBPNCVNR-SKCUWOTOSA-N 0.000 description 1
229950004826 capromorelin Drugs 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
230000004706 cardiovascular dysfunction Effects 0.000 description 1
238000005341 cation exchange Methods 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000007795 chemical reaction product Substances 0.000 description 1
238000011210 chromatographic step Methods 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
239000012501 chromatography medium Substances 0.000 description 1
229960002174 ciprofibrate Drugs 0.000 description 1
KPSRODZRAIWAKH-UHFFFAOYSA-N ciprofibrate Chemical compound C1=CC(OC(C)(C)C(O)=O)=CC=C1C1C(Cl)(Cl)C1 KPSRODZRAIWAKH-UHFFFAOYSA-N 0.000 description 1
229960001214 clofibrate Drugs 0.000 description 1
KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 description 1
229960002896 clonidine Drugs 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000013065 commercial product Substances 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000013256 coordination polymer Substances 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
150000001933 cycloheptenes Chemical class 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
230000001086 cytosolic effect Effects 0.000 description 1
230000007812 deficiency Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
239000003599 detergent Substances 0.000 description 1
229960001894 detomidine Drugs 0.000 description 1
JXMXDKHEZLKQPB-UHFFFAOYSA-N detomidine Chemical compound CC1=CC=CC(CC=2[N]C=NC=2)=C1C JXMXDKHEZLKQPB-UHFFFAOYSA-N 0.000 description 1
238000011026 diafiltration Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229960003913 econazole Drugs 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
208000028208 end stage renal disease Diseases 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
RTZKZFJDLAIYFH-UHFFFAOYSA-N ether Substances CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
229950001583 examorelin Drugs 0.000 description 1
229960000255 exemestane Drugs 0.000 description 1
210000003722 extracellular fluid Anatomy 0.000 description 1
229950011548 fadrozole Drugs 0.000 description 1
229960002297 fenofibrate Drugs 0.000 description 1
YMTINGFKWWXKFG-UHFFFAOYSA-N fenofibrate Chemical compound C1=CC(OC(C)(C)C(=O)OC(C)C)=CC=C1C(=O)C1=CC=C(Cl)C=C1 YMTINGFKWWXKFG-UHFFFAOYSA-N 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
229940125753 fibrate Drugs 0.000 description 1
238000001914 filtration Methods 0.000 description 1
229960004421 formestane Drugs 0.000 description 1
OSVMTWJCGUFAOD-KZQROQTASA-N formestane Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CCC2=C1O OSVMTWJCGUFAOD-KZQROQTASA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000004927 fusion Effects 0.000 description 1
108020001507 fusion proteins Proteins 0.000 description 1
102000037865 fusion proteins Human genes 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000005227 gel permeation chromatography Methods 0.000 description 1
229960003627 gemfibrozil Drugs 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
229940063135 genotropin Drugs 0.000 description 1
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 1
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 1
108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 1
239000003324 growth hormone secretagogue Substances 0.000 description 1
108010085742 growth hormone-releasing peptide-2 Proteins 0.000 description 1
239000008241 heterogeneous mixture Substances 0.000 description 1
125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
108010070965 hexarelin Proteins 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
239000000960 hypophysis hormone Substances 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
229940068935 insulin-like growth factor 2 Drugs 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
210000001596 intra-abdominal fat Anatomy 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
238000010829 isocratic elution Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
229960003881 letrozole Drugs 0.000 description 1
HPJKCIUCZWXJDR-UHFFFAOYSA-N letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
230000004130 lipolysis Effects 0.000 description 1
YFVGRULMIQXYNE-UHFFFAOYSA-M lithium;dodecyl sulfate Chemical compound [Li+].CCCCCCCCCCCCOS([O-])(=O)=O YFVGRULMIQXYNE-UHFFFAOYSA-M 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
108010000594 mecasermin Proteins 0.000 description 1
229960001311 mecasermin Drugs 0.000 description 1
229960002140 medetomidine Drugs 0.000 description 1
HRLIOXLXPOHXTA-UHFFFAOYSA-N medetomidine Chemical compound C=1C=CC(C)=C(C)C=1C(C)C1=CN=C[N]1 HRLIOXLXPOHXTA-UHFFFAOYSA-N 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000006371 metabolic abnormality Effects 0.000 description 1
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 1
229960003105 metformin Drugs 0.000 description 1
125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 description 1
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
229960002509 miconazole Drugs 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229950001628 netoglitazone Drugs 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
210000004789 organ system Anatomy 0.000 description 1
239000002245 particle Substances 0.000 description 1
125000004817 pentamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
125000001151 peptidyl group Chemical group 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
230000003285 pharmacodynamic effect Effects 0.000 description 1
125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
239000011574 phosphorus Substances 0.000 description 1
229910052698 phosphorus Inorganic materials 0.000 description 1
230000006461 physiological response Effects 0.000 description 1
PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
229960001697 physostigmine Drugs 0.000 description 1
229960005095 pioglitazone Drugs 0.000 description 1
150000003053 piperidines Chemical class 0.000 description 1
208000003068 pituitary dwarfism Diseases 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
230000003169 placental effect Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920003196 poly(1,3-dioxolane) Polymers 0.000 description 1
239000002861 polymer material Substances 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
230000004362 positive regulation of skeletal muscle tissue growth Effects 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
229960000208 pralmorelin Drugs 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
235000013772 propylene glycol Nutrition 0.000 description 1
239000012264 purified product Substances 0.000 description 1
229960002290 pyridostigmine Drugs 0.000 description 1
150000003235 pyrrolidines Chemical class 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
229920005604 random copolymer Polymers 0.000 description 1
108010077161 rat insulin-like growth factor-1 Proteins 0.000 description 1
239000011535 reaction buffer Substances 0.000 description 1
238000001525 receptor binding assay Methods 0.000 description 1
229950005713 reglitazar Drugs 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
238000009256 replacement therapy Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
238000005185 salting out Methods 0.000 description 1
238000005070 sampling Methods 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
230000028327 secretion Effects 0.000 description 1
125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
WGWPRVFKDLAUQJ-MITYVQBRSA-N sermorelin Chemical compound C([C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(N)=O)C1=CC=C(O)C=C1 WGWPRVFKDLAUQJ-MITYVQBRSA-N 0.000 description 1
229960002758 sermorelin Drugs 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
210000002356 skeleton Anatomy 0.000 description 1
230000003093 somatogenic effect Effects 0.000 description 1
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
229960000553 somatostatin Drugs 0.000 description 1
108010033419 somatotropin-binding protein Proteins 0.000 description 1
108700031632 somatrem Proteins 0.000 description 1
229960003259 somatrem Drugs 0.000 description 1
229960004532 somatropin Drugs 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
108010064878 tabimorelin Proteins 0.000 description 1
229950008131 tabimorelin Drugs 0.000 description 1
230000008685 targeting Effects 0.000 description 1
WBWWGRHZICKQGZ-GIHLXUJPSA-N taurocholic acid Chemical compound C([C@@H]1C[C@H]2O)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@@H]([C@@H](CCC(=O)NCCS(O)(=O)=O)C)[C@@]2(C)[C@H](O)C1 WBWWGRHZICKQGZ-GIHLXUJPSA-N 0.000 description 1
125000004149 thio group Chemical group *S* 0.000 description 1
238000013519 translation Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
125000003258 trimethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])[*:1] 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 1
210000001835 viscera Anatomy 0.000 description 1
229960001771 vorozole Drugs 0.000 description 1
XLMPPFTZALNBFS-INIZCTEOSA-N vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Gynecology & Obstetrics (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Pregnancy & Childbirth (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Pain & Pain Management (AREA)
Hospice & Palliative Care (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

CA002577999A 2004-08-31 2005-08-25 Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues Abandoned CA2577999A1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US60594504P	2004-08-31	2004-08-31
US60/605,945		2004-08-31
PCT/IB2005/002939 WO2006024953A2 (fr)	2004-08-31	2005-08-25	Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues

Publications (1)

Publication Number	Publication Date
CA2577999A1 true CA2577999A1 (fr)	2006-03-09

Family

ID=35708806

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002577999A Abandoned CA2577999A1 (fr)	2004-08-31	2005-08-25	Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues

Country Status (24)

Country	Link
EP (1)	EP1789092A2 (fr)
JP (1)	JP2008511610A (fr)
KR (1)	KR20070042567A (fr)
CN (1)	CN101010105A (fr)
AP (1)	AP2007003919A0 (fr)
AR (1)	AR050851A1 (fr)
AU (1)	AU2005278903A1 (fr)
BR (1)	BRPI0515118A (fr)
CA (1)	CA2577999A1 (fr)
CR (1)	CR8942A (fr)
EA (1)	EA200700380A1 (fr)
EC (1)	ECSP077281A (fr)
GT (1)	GT200500235A (fr)
IL (1)	IL181085A0 (fr)
MA (1)	MA28908B1 (fr)
MX (1)	MX2007002441A (fr)
NL (1)	NL1029828C2 (fr)
NO (1)	NO20071322L (fr)
PE (1)	PE20060654A1 (fr)
TN (1)	TNSN07078A1 (fr)
TW (1)	TW200621291A (fr)
UY (1)	UY29088A1 (fr)
WO (1)	WO2006024953A2 (fr)
ZA (1)	ZA200701802B (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO1999003887A1 (fr)	1997-07-14	1999-01-28	Bolder Biotechnology, Inc.	Derives d'hormone de croissance et proteines associees
US7495087B2 (en)	1997-07-14	2009-02-24	Bolder Biotechnology, Inc.	Cysteine muteins in the C-D loop of human interleukin-11
IL144259A0 (en)	1999-01-14	2002-05-23	Bolder Biotechnology Inc	Methods for making proteins containing free cysteine residues
US7855279B2 (en)	2005-09-27	2010-12-21	Amunix Operating, Inc.	Unstructured recombinant polymers and uses thereof
EP1834963A1 (fr) *	2006-03-13	2007-09-19	Siegfried Ltd.	Conjugues de proteines et de dipolymeres et leurs procedes de preparation
CN101448525A (zh) *	2006-05-12	2009-06-03	东亚制药株式会社	聚乙二醇-干扰素α缀合物
JP2008069073A (ja) *	2006-09-12	2008-03-27	Yokohama Tlo Co Ltd	ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko)	2006-11-17	2011-11-04	동아제약주식회사	폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es)	2007-08-16	2009-01-02	Pharmaessentia Corp	Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
RU2483081C2 (ru) *	2008-07-23	2013-05-27	Ханми Сайенс Ко.,Лтд.,Kr	Полипептидный комплекс, содержащий непептидильный полимер, обладающий тремя функциональными концами
KR101533757B1 (ko)	2008-07-31	2015-07-03	파마이센시아 코퍼레이션	펩티드-중합체 접합체
US8535655B2 (en)	2008-10-10	2013-09-17	Polyactiva Pty Ltd.	Biodegradable polymer—bioactive moiety conjugates
EP2340271B1 (fr) *	2008-10-10	2018-12-05	PolyActiva Pty Ltd.	Conjugués polymère-agent bioactif
HUE030895T2 (en) *	2008-10-10	2017-06-28	Polyactiva Pty Ltd	Biodegradable polymer-bioactive group conjugates
EA020843B1 (ru)	2009-02-03	2015-02-27	Амуникс Оперейтинг Инк.	Удлиненные рекомбинантные полипептиды и содержащие их композиции
US8680050B2 (en)	2009-02-03	2014-03-25	Amunix Operating Inc.	Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
US8703717B2 (en)	2009-02-03	2014-04-22	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
US9849188B2 (en)	2009-06-08	2017-12-26	Amunix Operating Inc.	Growth hormone polypeptides and methods of making and using same
CN105963710A (zh)	2009-08-06	2016-09-28	诺沃—诺迪斯克保健股份有限公司	具有延长的体内功效的生长激素
CN101831067A (zh) *	2010-05-31	2010-09-15	王二新	聚乙二醇脂类缀合物及其在制备药物中的应用
EP2446898A1 (fr)	2010-09-30	2012-05-02	Laboratorios Del. Dr. Esteve, S.A.	Utilisation de l'hormone de croissance pour améliorer la réponse immunitaire chez des patients immunodéprimés
CN102367290B (zh) *	2011-04-26	2013-05-08	厦门赛诺邦格生物科技有限公司	链官能化的多级支化聚乙二醇及其合成方法
DK2947111T3 (en) *	2013-01-17	2018-05-07	Xiamen Sinopeg Biotech Co Ltd	MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME
CN104877127B (zh)	2015-06-23	2017-11-10	厦门赛诺邦格生物科技股份有限公司	一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
WO2016073825A1 (fr)	2014-11-06	2016-05-12	Pharmaessentia Corporation	Régime posologique pour l'interféron pégylé
EP3731873B1 (fr) *	2017-12-29	2022-01-26	F. Hoffmann-La Roche AG	Procédé de fournir des protéines monopégylée
CN111801120A (zh)	2017-12-29	2020-10-20	豪夫迈·罗氏有限公司	用于提供聚乙二醇化蛋白质组合物的方法
EP3731871B1 (fr) *	2017-12-29	2023-10-04	F. Hoffmann-La Roche AG	Procédé de fournir des protéines pégylée

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2147192A (en) *	1991-06-28	1993-01-25	Genentech Inc.	Method of stimulating immune response using growth hormone
JP3092531B2 (ja) *	1996-11-05	2000-09-25	日本油脂株式会社	コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
WO1999003887A1 (fr) *	1997-07-14	1999-01-28	Bolder Biotechnology, Inc.	Derives d'hormone de croissance et proteines associees
JP3921781B2 (ja) *	1998-02-12	2007-05-30	日本油脂株式会社	カルボキシル基含有ポリオキシアルキレン化合物
IL144259A0 (en) *	1999-01-14	2002-05-23	Bolder Biotechnology Inc	Methods for making proteins containing free cysteine residues
MXPA04004809A (es) *	2001-11-20	2004-08-11	Pharmacia Corp	Conjugados de hormona de crecimiento humana modificada quimicamente.
ES2897470T3 (es) *	2002-09-09	2022-03-01	Nektar Therapeutics	Alcanales poliméricos solubles en agua
JP4412461B2 (ja) *	2002-11-20	2010-02-10	日油株式会社	修飾された生体関連物質、その製造方法および中間体
US7208145B2 (en) *	2002-12-31	2007-04-24	Nektar Therapeutics Al, Corporation	Polymeric reagents comprising a ketone or a related functional group
AU2004251602B2 (en) *	2003-05-23	2010-05-13	Nektar Therapeutics	PEG derivatives having an amidocarbonate linkage

2005
- 2005-08-25 AU AU2005278903A patent/AU2005278903A1/en not_active Abandoned
- 2005-08-25 CN CNA2005800291171A patent/CN101010105A/zh active Pending
- 2005-08-25 MX MX2007002441A patent/MX2007002441A/es unknown
- 2005-08-25 WO PCT/IB2005/002939 patent/WO2006024953A2/fr active Application Filing
- 2005-08-25 BR BRPI0515118-0A patent/BRPI0515118A/pt not_active IP Right Cessation
- 2005-08-25 JP JP2007529040A patent/JP2008511610A/ja active Pending
- 2005-08-25 EP EP05784225A patent/EP1789092A2/fr not_active Withdrawn
- 2005-08-25 CA CA002577999A patent/CA2577999A1/fr not_active Abandoned
- 2005-08-25 KR KR1020077004912A patent/KR20070042567A/ko not_active Application Discontinuation
- 2005-08-25 AP AP2007003919A patent/AP2007003919A0/xx unknown
- 2005-08-25 EA EA200700380A patent/EA200700380A1/ru unknown
- 2005-08-26 PE PE2005000991A patent/PE20060654A1/es not_active Application Discontinuation
- 2005-08-29 AR ARP050103612A patent/AR050851A1/es unknown
- 2005-08-29 UY UY29088A patent/UY29088A1/es not_active Application Discontinuation
- 2005-08-30 TW TW094129583A patent/TW200621291A/zh unknown
- 2005-08-30 NL NL1029828A patent/NL1029828C2/nl not_active IP Right Cessation
- 2005-08-30 GT GT200500235A patent/GT200500235A/es unknown
2007
- 2007-01-31 IL IL181085A patent/IL181085A0/en unknown
- 2007-02-26 CR CR8942A patent/CR8942A/es not_active Application Discontinuation
- 2007-02-27 EC EC2007007281A patent/ECSP077281A/es unknown
- 2007-02-27 TN TNP2007000078A patent/TNSN07078A1/fr unknown
- 2007-02-28 MA MA29724A patent/MA28908B1/fr unknown
- 2007-02-28 ZA ZA200701802A patent/ZA200701802B/xx unknown
- 2007-03-09 NO NO20071322A patent/NO20071322L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
GT200500235A (es)	2006-03-21
EP1789092A2 (fr)	2007-05-30
IL181085A0 (en)	2007-07-04
MX2007002441A (es)	2007-05-04
NL1029828A1 (nl)	2006-03-01
JP2008511610A (ja)	2008-04-17
UY29088A1 (es)	2006-03-31
ECSP077281A (es)	2007-03-29
TNSN07078A1 (fr)	2008-06-02
EA200700380A1 (ru)	2007-10-26
PE20060654A1 (es)	2006-08-12
CN101010105A (zh)	2007-08-01
AP2007003919A0 (en)	2007-02-28
WO2006024953A2 (fr)	2006-03-09
ZA200701802B (en)	2008-08-27
TW200621291A (en)	2006-07-01
NO20071322L (no)	2007-05-29
BRPI0515118A (pt)	2008-07-01
WO2006024953A3 (fr)	2007-01-18
KR20070042567A (ko)	2007-04-23
AU2005278903A1 (en)	2006-03-09
AR050851A1 (es)	2006-11-29
NL1029828C2 (nl)	2006-10-20
MA28908B1 (fr)	2007-10-01
CR8942A (es)	2007-08-16

Legal Events

Date	Code	Title	Description
2007-02-23	EEER	Examination request
2009-08-25	FZDE	Discontinued

Publication	Publication Date	Title
CA2577999A1 (fr)	2006-03-09	Conjugues d'hormone de croissance humaine polyethylene glycol ramifie, processus de preparation et procedes d'utilisation de ces conjugues
EP1715887B1 (fr)	2007-06-20	Conjugues de l'hormone de croissance humaine monopegyles sur le plan n-terminal, procede de preparation et l'utilisation desdits conjugues
AU2002356990A1 (en)	2003-06-10	Chemically-modified human growth hormone conjugates
US20030171285A1 (en)	2003-09-11	Chemically-modified human growth hormone conjugates
US20040127417A1 (en)	2004-07-01	N-terminally monopegylated human growth hormone conjugates and process for their preparation
US20040038892A1 (en)	2004-02-26	Chemically-modified human growth hormone conjugates
Finn	2009	PEGylation of human growth hormone: strategies and properties
MXPA06008888A (en)	2007-04-10	N-terminally monopegylated human growth hormone conjugates, process for their preparation, and methods of use thereof